spacer
home > white papers > Choosing the Right CMO for HPAPI Manufacturing - AMRI
WHITE PAPERS
logo_AMRI4.jpg

AMRI

phone +1 1-518-512-2000
email info@amriglobal.com
web http://www.amriglobal.com
email 26 Corporate Circle, PO box 15098, Albany NY

Choosing the Right CMO for HPAPI Manufacturing

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

PharmaFluidics awarded VLAIO research grant

Ghent, Belgium – June 2, 2020 PharmaFluidics NV, innovative player in the field of analytical chromatography with its unique high-resolution µPAC™ micro-Chip technology, announces that it has been awarded a € 613 k grant from Flanders’ Innovation & Entrepreneurship Agency (VLAIO). The grant will run over two years and will support the further optimization of PharmaFluidics’ manufacturing flow, and to develop complementary new surface-modified µPAC™ products.
More info >>


White Papers

Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling

Sartorius Group

The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >>


Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement